Companies / BOC Sciences / Cemiplimab
BOC Sciences

Cemiplimab | BOC Sciences

Cemiplimab is a PD-1 monoclonal antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab has been approved for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.